Dyfrig A. Hughes

Dyfrig A. Hughes

Rowland Hill Street
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 270 publications

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

Journal: British journal of clinical pharmacology

Published: May 06, 2026

Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries.

Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: May 01, 2026

'I Didn't Even Associate the Two Together at All': A Qualitative Study of 'Information Work' Undertaken by Parents and Their Children With Epilepsy to Make Sense of Sleep and Seizures.

'I Didn't Even Associate the Two Together at All': A Qualitative Study of 'Information Work' Undertaken by Parents and Their Children With Epilepsy to Make Sense of Sleep and Seizures.

Journal: Health expectations : an international journal of public participation in health care and health policy

Published: April 10, 2026

ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

Journal: British journal of clinical pharmacology

Published: March 31, 2026

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

Journal: British journal of clinical pharmacology

Published: March 11, 2026

Prophylactic antibiotics to prevent chest infections in children with neurological impairment: the PARROT RCT.

Prophylactic antibiotics to prevent chest infections in children with neurological impairment: the PARROT RCT.

Journal: Health technology assessment (Winchester, England)

Published: March 09, 2026

Comment on "The Importance of Structured Expert Elicitation to Inform Outcomes Following Treatment Discontinuation: Evidence Assessment Group Perspective".

Comment on "The Importance of Structured Expert Elicitation to Inform Outcomes Following Treatment Discontinuation: Evidence Assessment Group Perspective".

Journal: PharmacoEconomics

Published: January 12, 2026

Guideline for the Measurement, Analysis and Reporting of Medication Adherence during the Run-in phase of clinical trials (MARMAR).

Guideline for the Measurement, Analysis and Reporting of Medication Adherence during the Run-in phase of clinical trials (MARMAR).

Journal: Trials

Published: December 18, 2025

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

Journal: British journal of clinical pharmacology

Published: October 19, 2025

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics.

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics.

Journal: British journal of clinical pharmacology

Published: August 20, 2025

Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based treatment for colorectal cancer in Wales.

Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based treatment for colorectal cancer in Wales.

Journal: British journal of clinical pharmacology

Published: August 20, 2025

Exploring patient and professional perspectives on implementing pharmacogenomic testing in the UK primary care setting and estimating the cost-effectiveness: a mixed-methods study protocol.

Exploring patient and professional perspectives on implementing pharmacogenomic testing in the UK primary care setting and estimating the cost-effectiveness: a mixed-methods study protocol.

Journal: BMJ open

Published: July 23, 2025

Showing 1-12 of 270

Last Updated: 09/26/2026